Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Ongoing research into ulcerative colitis continues to uncover new treatment options, therapies, and ways to improve patient outcomes. Advances in biologic treatments and personalized medicine hold ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

Biologics block specific cytokines (inflammatory ... There are several treatments for ulcerative colitis (UC), including JAK inhibitors. JAK inhibitors are a type of medication to manage moderate ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new ... to or can’t tolerate other biologic therapies for UC.